Education
About Us
Working with TipRanks
Follow Us
Novartis (DE:NOT)
XETRA:NOT
NOT Stock Chart & Stats
Day’s Range― - ―
52-Week Range€79.74 - €111.38
Previous CloseN/A
Volume24.84K
Average Volume (3M)1.13K
Market Cap
€201.66B
Enterprise Value€208.96B
Total Cash (Recent Filing)€7.00B
Total Debt (Recent Filing)€32.64B
Price to Earnings (P/E)16.7
Beta0.21
Next Earnings
Oct 28, 2025EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding2,112,421,900
10 Day Avg. Volume660
30 Day Avg. Volume1,132
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€109.14Price Target Upside3.06% Upside
Rating ConsensusHold
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Pipeline OpportunitiesThe pipeline for FY26 is interesting, with Pelacarsen showing promise in cardiovascular risk reduction and Abelacimab seen as a multi-billion dollar opportunity.
Product GrowthAnalysts see three possible peak sales upgrades for Kisqali, Kesimpta, and Scemblix, indicating strong growth potential.
Product PotentialThere is confidence in Ianalumab's multi-billion potential in treating Sjogren’s syndrome, with positive feedback from physicians and expectations of rapid adoption.
Bears Say
Generic CompetitionAs generic competition impact steps up in the coming years, Novartis' growth rate is expected to structurally reset lower.
Growth OutlookDespite likely EPS momentum and a decent catalyst path, analysts remain cautious due to the lower growth outlook and patent exposure.
Valuation ConcernsThe recommendation remains Neutral due to valuation concerns and slowing growth.
Novartis AG News
NOT FAQ
What was Novartis’s price range in the past 12 months?
Novartis lowest stock price was €79.74 and its highest was €111.38 in the past 12 months.
What is Novartis’s market cap?
Novartis’s market cap is €201.66B.
When is Novartis’s upcoming earnings report date?
Novartis’s upcoming earnings report date is Oct 28, 2025 which is in 27 days.
How were Novartis’s earnings last quarter?
Novartis released its earnings results on Jul 17, 2025. The company reported €2.062 earnings per share for the quarter, beating the consensus estimate of €2.003 by €0.059.
Is Novartis overvalued?
According to Wall Street analysts Novartis’s price is currently Undervalued.
Does Novartis pay dividends?
Novartis does not currently pay dividends.
What is Novartis’s EPS estimate?
Novartis’s EPS estimate is 1.92.
How many shares outstanding does Novartis have?
Novartis has 2,112,421,900 shares outstanding.
What happened to Novartis’s price movement after its last earnings report?
Novartis reported an EPS of €2.062 in its last earnings report, beating expectations of €2.003. Following the earnings report the stock price went down -1.686%.
Which hedge fund is a major shareholder of Novartis?
Currently, no hedge funds are holding shares in DE:NOT
Company Description
Novartis
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOT Stock 12 Month Forecast
Average Price Target
€109.14
▲(3.06% Upside)
Technical Analysis
Options Prices
Currently, No data available
---